Table 2 Demographic data of patients with cerebral hemorrhage divided by dead or alive and control patients
Died (N = 32) | Survived (N = 67) | P value | CH all (N = 99) | Control (N = 339) | P value | |
|---|---|---|---|---|---|---|
Age (year) | 64.9 ± 9.2 | 64.7 ± 11.5 | 0.7 | 64.8 ± 10.7 | 67.4 ± 13.3 | 0.06 |
Male (%) | 62.5 | 68.7 | 0.5 | 66.7 | 57.2 | 0.09 |
HD vintage (months)a | 85 (30–169) | 88 (27–177) | 0.7 | 87 (29–177) | 56 (23–122) | 0.04 |
Cause of ESRD | ||||||
 Chronic glomerulonephritis (%) | 28 | 48 | 41 | 38 | ||
 Diabetes (%) | 44 | 31 | 35 | 28 | ||
 Nephrosclerosis (%) | 13 | 7 | 9 | 17 | ||
 ADPKD (%) | 6 | 7 | 7 | 4 | ||
 Others (%) | 6 | 6 | 6 | 6 | ||
 Unknown (%) | 3 | 0 | 0.3 | 1 | 7 | 0.02 |
Past history | ||||||
 Diabetes mellitus (%) | 44 | 37 | 0.5 | 39 | 35 | 0.4 |
 Ischemic heart disease (%) | 34 | 9 | 0.002 | 17 | 34 | < 0.001 |
 Atrial fibrillation (%) | 3 | 12 | 0.11 | 9 | 10 | 0.8 |
 Heart valve repair or replacement (%) | 16 | 2 | 0.008 | 6 | 4 | 0.2 |
 History of cerebral infarction (%) | 31 | 34 | 0.8 | 33 | 25 | 0.09 |
 History of cerebral hemorrhage (%) | 16 | 13 | 0.8 | 14 | 6 | 0.02 |
Medication | ||||||
 Number of antihypertensive drugs | 1.6 ± 1.2 | 1.9 ± 1.3 | 0.3 | 1.8 ± 1.3 | 1.6 ± 1.5 | 0.09 |
 Antiplatelet use (%) | 65 | 36 | 0.008 | 45 | 39 | 0.3 |
 Warfarin use (%) | 25 | 7 | 0.02 | 13 | 7 | 0.07 |
 Statin use (%) | 17 | 9 | 0.3 | 11 | 16 | 0.3 |
 Vitamin D use (%) | 54 | 66 | 0.3 | 62 | 67 | 0.1 |
 Phosphate binder use (%) | 71 | 68 | 0.8 | 69 | 65 | 0.5 |
 CaCO3 use (%) | 52 | 47 | 0.7 | 48 | 48 | 1.0 |
 Cinacalcet use (%) | 13 | 18 | 0.6 | 16 | 17 | 0.9 |
 Walking independently (mRS≦3) (%) | 77 | 86 | 0.2 | 83 | 80 | 0.5 |
Dialysis conditions | ||||||
 Dialyzing time (hr)a | 4 (3–4) | 4 (3.5–4) | 0.7 | 4 (3.5–4) | 4 (3–4) | 0.02 |
 Dry weight (kg) | 52.4 ± 11.5 | 53.7 ± 11.5 | 0.4 | 53.3 ± 11.5 | 52.1 ± 11.0 | 0.3 |
 Fluid removal per dry weight proximate to the onset (%) | 3.14 ± 2.04 | 3.35 ± 1.71 | 0.6 | 3.29 ± 1.81 | 3.10 ± 1.74 | 0.3 |
 Dialysate Ca concentration (mEq/L) | 2.81 ± 0.14 | 2.79 ± 0.18 | 0.7 | 2.79 ± 0.17 | 2.75 | NA |
 Online HDF (%) | 13 | 7 | 0.4 | 9 | 22 | 0.002 |
sBP pre-HD proximate to the onset (mmHg) | 167 ± 31 | 167 ± 22 | 1.0 | 167 ± 25 | 150 ± 24 | < 0.001 |
dBP pre-HD proximate to the onset (mmHg) | 86 ± 14 | 87 ± 16 | 0.8 | 87 ± 16 | 78 ± 13 | < 0.001 |
Pulse pressure proximate to the onset (mmHg) | 81 ± 24 | 80 ± 15 | 1.0 | 80 ± 18 | 72 ± 21 | < 0.001 |
 ESA (U/week) | 6719 ± 3592 | 6296 ± 4556 | 0.6 | 6435 ± 4247 | 5513 ± 4396 | 0.03 |
 Epoetin (%) | 38 | 28 | 31 | 9 | ||
 Darbepoetin (%) | 41 | 37 | 38 | 47 | ||
 CERA (%) | 13 | 18 | 16 | 27 | ||
 Intravenous iron use (%) | 22 | 27 | 0.6 | 25 | 19 | 0.08 |
Laboratory parameters | ||||||
 Hb (g/dL) | 10.6 ± 1.9 | 10.6 ± 1.5 | 0.4 | 10.6 ± 1.7 | 10.8 ± 1.4 | 0.09 |
 Ferritin (ng/mL)a | 139 (54–284) | 71 (31–167) | 0.095 | 85 (34–212) | 53 (21–154) | 0.03 |
 TSAT (%) | 21.3 ± 11.3 | 24.4 ± 12.9 | 0.4 | 23.4 ± 12.4 | 24.3 ± 13.0 | 0.6 |
 BUN (mg/dL) | 61.4 ± 20.7 | 60.2 ± 14.9 | 0.8 | 60.6 ± 16.8 | 68.1 ± 18.2 | < 0.001 |
 Creatinine (mg/dL) | 9.1 ± 3.2 | 10.0 ± 3.1 | 0.4 | 9.8 ± 3.1 | 10.2 ± 3.4 | 0.2 |
 Corrected serum calcium (mg/dL) | 9.93 ± 0.91 | 9.27 ± 0.86 | 0.001 | 9.48 ± 0.93 | 9.22 ± 0.92 | 0.01 |
 Phosphate (mg/dL) | 5.47 ± 2.09 | 4.93 ± 1.47 | 0.3 | 5.09 ± 1.68 | 5.58 ± 1.57 | 0.007 |
 iPTH (pg/mL)a | 122 (45–319) | 124 (45–202) | 0.7 | 124 (45–202) | 72 (28–155) | 0.007 |
 ALP (IU/L) | 305 ± 103 | 285 ± 143 | 0.14 | 291 ± 131 | 282 ± 133 | 0.4 |
 Serum albumin (g/dL) | 3.41 ± 0.56 | 3.62 ± 0.50 | 0.07 | 3.55 ± 0.53 | 3.56 ± 0.43 | 0.9 |
 CRP (mg/dL)a | 0.39 (0.09–0.69) | 0.17 (0.10–0.61) | 0.3 | 0.20 (0.09–0.65) | 0.18 (0.07–0.53) | 0.2 |
 T-Chol (mg/dL) | 152 ± 35 | 156 ± 38 | 0.9 | 155 ± 37 | 162 ± 37 | 0.07 |
 Triglyceride (mg/dL) | 102 ± 60 | 89 ± 44 | 0.5 | 93 ± 49 | 106 ± 64 | 0.2 |